@ShorelineBio will present at the 2024 Stifel Healthcare Conference, next week in New York. We invite you to attend our presentation to learn more about Shoreline’s approach to developing disease-modifying iNK cell therapies for autoimmune disorders.
https://t.co/0q62dANkuf
Meet Chad Viergever, our Sr. Manager of Corporate Development at @ShorelineBio. Originally from Sacramento, CA, Chad's journey led him to San Diego, where he found a love for the area and a passion for the life sciences.
Join our team today: https://t.co/buF1X3yPRN
#CellTherapy
Meet Suping Peng, our dedicated senior scientist in our Natural Killer Cell group here at @ShorelineBio. Each member of our team is driven by a shared passion to develop groundbreaking products that will positively impact patients' lives. #EmployeeSpotlight
Meet Jen, our invaluable Sr. Scientist in our analytical dev group here at @ShorelineBio. Jen is dedicated to turning the brilliant ideas of our research team into life-saving cancer treatments, all while adding her unique touch of fun and charm to her work. #EmployeeSpotlight
The @ShorelineBio team would like to extend our sincere gratitude this holiday season for supporting our mission as we fight the war against cancer. May this holiday season give you many reasons to smile, and we wish you a happy, healthy, and prosperous New Year.
We are thrilled to announce Vanessa Jacoby's inclusion in the Top 50 Diverse Board Candidate list, a prestigious recognition by @equilarinc and the @Nasdaq Center for Board Excellence.
Explore the full list of Top 50 Diverse Board Candidates here: https://t.co/wIcfYwW9Jo
Meet David Murray, a member of our genome editing team at @ShorelineBio! Dave is a pioneer in CRISPR-based gene editing, focusing on knocking out genes that can hinder a cell's ability to target cancer & knocking in genes that can enhance that ability.
https://t.co/buF1X3yi2f
Our team is the foundation of what makes @ShorelineBio special & we are thrilled to introduce our Employee Spotlight Video Series. This series showcases a few of our brave & talented employees behind our next-gen iPSC-derived cell therapies.
https://t.co/LOLw9AyDIS
#Bloopers
Shoreline's intelligent engineering is revolutionizing the fight against cancer with next-gen induced Pluripotent Stem Cell (iPSC)-derived natural killer (iNK) cells and macrophages (iMACs). Curious to learn more?
#iNK#Patients#Cancer#CellTherapy#OncologyResearch
At @ShorelineBio, we’re unlocking the power of cutting-edge gene editing with our advanced iPSC platform. If you’re passionate about advancing the future of cell therapies, check out our open positions and join our team!
Join our team: https://t.co/buF1X3yPRN
At @shorelinebio, we strive to create an industry-leading culture to maximize the potential of our diverse team. We're excited to welcome Steve Potter to our Executive team as we strive to win the war on cancer with our differentiated pipeline of immunotherapies.
#CellTherapy
We are delighted to share the publication of data in Nature Biotechnology on the novel genome editing platform called #SLEEK, pioneered by our partner, @editasmed. @ShorelineBio has an exclusive license to the SLEEK technology for all iNK & iMACs for oncology indications.